- Home
- Companies
- north america
- therapeutic candidate
Show results for
Refine by
Therapeutic Candidate Suppliers In North America
30 companies found
based inDurham, NORTH CAROLINA (USA)
Cancer is the second leading cause of death in the U.S. and metastatic disease remains predominantly incurable. New cancer cases and healthcare costs continue to increase year-over-year. Precision medicine aims to select the most effective ...
Xilis’ rapid and scalable patient-derived MicroOrganoSphere (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development. Compared to conventional patient-derived models, MOS provides faster, ...
based inAustin, TEXAS (USA)
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this ...
based inLeiden, NETHERLANDS
We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling ...
Profiling and screening of your compounds with a high throughput barrier integrity assay on our established Caco-2 intestinal model. OrganoServices are available for multiple assays to allow compound profiling and/or screening in human-relevant, ...
based inToronto, ONTARIO (CANADA)
Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI. Programming RNA Therapies Any Gene, Any Genetic Condition. Revolutions in AI, RNA biology and automation ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
based inBozeman, MONTANA (USA)
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections. Microbion is dedicated to developing ...
based inProvidence, RHODE ISLAND (USA)
Ocean Biomedical is a 21st century biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary ...
based inSan Carlos, CALIFORNIA (USA)
Developing live biotherapeutics to prevent and treat diseases of high unmet medical need. We leverage our deep knowledge of the human microbiome and its regulatory and developmental functions to develop live biotherapeutic products (LBPs) and ...
Siolta’s Precision Symbiotics Platform enables rapid LBP development. A platform focused on translating microbiome science into novel therapeutics for a healthier world. Siolta’s patient-centric platform leverages our ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
We are building an active pipeline of products for human health by applying our proprietary and patented C1 technology to develop vaccines and antibodies for infectious and other diseases. Vaccine Development: The C1 platform is ready for full ...
based inRedwood City, CALIFORNIA (USA)
Juvena Therapeutics is a biotech company accelerating the development of regenerative therapeutics by unlocking the therapeutic potential of secreted proteins. Secreted proteins are a class of biologics with proven therapeutic potential that has ...
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. The characteristics of secreted proteins ...
based inBoston, MASSACHUSETTS (USA)
Founded by Flagship Pioneering, Valo is a mission-driven technology company that was created with the belief that the drug discovery and development process can and should be better—faster, less expensive, and with a higher probability of success. ...
Opal is the first end-to-end integrated drug discovery & development platform. Traditional, linear approaches to target discovery and drug development have created sub-optimized systems that are intrinsically disintegrated and ...
based inSan Carlos, CALIFORNIA (USA)
Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and ...
based inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
The first patient was dosed with our investigational genome editing treatment for transthyretin (ATTR) amyloidosis in November 2020. Our modular approach enables us to optimize the power and versatility of the CRISPR/Cas9 technology and, ...
based inSomerville, MASSACHUSETTS (USA)
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted ...
Our lead product candidate, CP101, is an orally administered, Complete Consortia product candidate initially targeting the prevention of recurrent CDI. The Centers for Disease Control and Prevention considers CDI to be one of the top three most ...
based inBerkeley, CALIFORNIA (USA)
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies. Actym is also developing a broad pipeline of additional therapeutic candidates intended to treat checkpoint refractory ...
Actym Therapeutics, based in Berkeley, CA, is a privately held biotechnology company focused on the discovery and development of novel immunotherapies to treat cancer. The company has developed an attenuated, microbial-based, technology platform ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
In the discovery of oncology therapeutics, Antibody-drug conjugates (ADCs) are rapidly gaining momentum, with hundreds of candidates advancing through clinical development. Whether your priority lies in assessing ...
based inNaples, FLORIDA (USA)
Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and ...
based inSunnyvale, CALIFORNIA (USA)
We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of ...
based inMadison, WISCONSIN (USA)
Vascular diseases afflict hundreds of millions of people worldwide. Many patients do not respond to standard treatments. We are developing regenerative medicines to address these unmet needs. Vascugen is dedicated to revolutionizing the standard of ...
Development of complex iPSC-based therapeutics benefits from an engineering mindset. Each layer of the development and manufacturing process is considered part of the ‘Full Stack’ that leads to finished product. An ...
based inSomerset, NEW JERSEY (USA)
As the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world, we conduct all our business responsibly and with integrity. Our ...
To date, over 600 different mAb and mAb fusions and over 160+ different recombinant proteins have been produced using the GPEx system, with 160+ clinical trials utilizing therapeutic candidates developed using GPEx ...
